Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation ; volume:102 ; number:8 ; day:22 ; month:6 ; year:2023 ; pages:2297-2298 ; date:8.2023
Annals of hematology ; 102, Heft 8 (22.6.2023), 2297-2298, 8.2023
- Urheber
-
Martino, Massimo
Gori, Mercedes
Porto, Gaetana
Pellicano, Maria
Santoro, Ludovica
Verduci, Chiara
Canale, Filippo Antonio
Loteta, Barbara
Moscato, Tiziana
Alati, Caterina
Ieracitano, Maria Consuelo
Cuzzocrea, Amelia
Altomonte, Maria
Florenzano, Maria Teresa
Morabito, Antonella
Irrera, Giuseppe
Naso, Virginia
Pugliese, Marta
Console, Giuseppe
Ferreri, Anna
Imbalzano, Lucrezia
Tripepi, Giovanni
Pitino, Annalisa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-023-05323-1
- URN
-
urn:nbn:de:101:1-2023101809190747468105
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martino, Massimo
- Gori, Mercedes
- Porto, Gaetana
- Pellicano, Maria
- Santoro, Ludovica
- Verduci, Chiara
- Canale, Filippo Antonio
- Loteta, Barbara
- Moscato, Tiziana
- Alati, Caterina
- Ieracitano, Maria Consuelo
- Cuzzocrea, Amelia
- Altomonte, Maria
- Florenzano, Maria Teresa
- Morabito, Antonella
- Irrera, Giuseppe
- Naso, Virginia
- Pugliese, Marta
- Console, Giuseppe
- Ferreri, Anna
- Imbalzano, Lucrezia
- Tripepi, Giovanni
- Pitino, Annalisa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
Altered t-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive t-cell therapy
Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim
Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation
Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
Altered t-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive t-cell therapy
Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim
Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation
Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
Altered t-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive t-cell therapy
Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim
Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation
Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation